Kathleen Mccarthy

Chief Scientific Officer & Co-Founder

Kathleen began her career by co-developing a treatment for Spinal Muscular Atrophy (SMA) as a pre-clinical scientist at the SMA Foundation. In this role she helped bring the first-ever small molecule therapeutic driving mRNA alternative splicing, to clinical trials in SMA. This drug candidate was bought by Roche in 2011 and Kathleen moved to Roc...

Roles at Skyhawk Therapeutics

  • Chief Scientific Officer & Co-Founder

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.